264 related articles for article (PubMed ID: 36982792)
21. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives.
Date T; Kuche K; Ghadi R; Kumar P; Jain S
Mol Pharm; 2022 May; 19(5):1325-1337. PubMed ID: 35437994
[TBL] [Abstract][Full Text] [Related]
22. Multi-action platinum(IV) prodrugs conjugated with COX-inhibiting NSAIDs.
Liu X; Wenisch D; Dahlke P; Jordan PM; Jakupec MA; Kowol CR; Liebing P; Werz O; Keppler BK; Weigand W
Eur J Med Chem; 2023 Sep; 257():115515. PubMed ID: 37295160
[TBL] [Abstract][Full Text] [Related]
23. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
[TBL] [Abstract][Full Text] [Related]
24. A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).
Ramu V; Gill MR; Jarman PJ; Turton D; Thomas JA; Das A; Smythe C
Chemistry; 2015 Jun; 21(25):9185-97. PubMed ID: 25950156
[TBL] [Abstract][Full Text] [Related]
25. Platinum(II) complexes of imidazophenanthroline-based polypyridine ligands as potential anticancer agents: synthesis, characterization, in vitro cytotoxicity studies and a comparative ab initio, and DFT studies with cisplatin, carboplatin, and oxaliplatin.
Alexander C; Nithyakumar A; Paul MWB; Arockia Samy N
J Biol Inorg Chem; 2018 Jul; 23(5):833-848. PubMed ID: 29934700
[TBL] [Abstract][Full Text] [Related]
26. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
27. Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
Buss I; Garmann D; Galanski MS; Weber G; Kalayda GV; Keppler BK; Jaehde U
J Inorg Biochem; 2011 May; 105(5):709-17. PubMed ID: 21450275
[TBL] [Abstract][Full Text] [Related]
28. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
29. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
30. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
31. Enhanced potency of a chloro-substituted polyaromatic platinum(II) complex and its platinum(IV) prodrug against lung cancer.
Baz J; Khoury A; Elias MG; Mansour N; Mehanna S; Hammoud O; Gordon CP; Taleb RI; Aldrich-Wright JR; Daher CF
Chem Biol Interact; 2024 Jan; 388():110834. PubMed ID: 38103879
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
33. Studies on the Complexation of Platinum(II) by Some 4-Nitroisoxazoles and Testing the Cytotoxic Activity of the Resulting Complexes.
Mastalarz H; Mastalarz A; Wietrzyk J; Milczarek M; Kochel A; Regiec A
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770951
[TBL] [Abstract][Full Text] [Related]
34. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
35. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
36. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
37. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
38. Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway.
Luo Z; Luo Y; Liang X; Lyu Q; Meng F; Chen X; Wang Y; Fang W; Li A; Zhou D
ACS Biomater Sci Eng; 2022 Jun; 8(6):2526-2536. PubMed ID: 35612599
[TBL] [Abstract][Full Text] [Related]
39. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
[TBL] [Abstract][Full Text] [Related]
40. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
